晶泰控股2025年度报告

( 於 開 曼 群 島 註 冊 成 立 之 有 限 公 司 )Stock Code股 份 代 號: 2 2 2 8(Incorporated in the Cayman Islands with limited liability) CONTENTS目錄 2Corporate Information5Financial Summary6Corporate Profile7Chairman’s Statement26Management Discussion and Analysis34Profiles of Directors and Senior Management42Corporate Governance Report63Report of Directors106Environmental, Social and Governance Report231Independent Auditor’s Report241Consolidated Statement of Profit or Loss242Consolidated Statement of Comprehensive Income243Consolidated Balance Sheet245Consolidated Statement of Changes in Equity247Consolidated Statement of Cash Flows249Notes to the Consolidated Financial Statements344Definitions 公司資料Corporate Information BOARD OF DIRECTORS 執行董事 Executive Directors Dr. Wen Shuhao(Chairman)Dr. Ma Jian(Chief Executive Officer)Dr. Lai LipengDr. Jiang Yide Alan 獨立非執行董事 Independent Non-executive Directors Mr. Law Cheuk Kin StephenMs. Chan Wing KiMr. Chow Ming Sang AUTHORISED REPRESENTATIVES Dr. Wen ShuhaoMs. Liu Shimei AUDIT COMMITTEE Mr. Law Cheuk Kin Stephen(Chairman)Ms. Chan Wing KiMr. Chow Ming Sang REMUNERATION COMMITTEE Mr. Law Cheuk Kin Stephen(Chairman)Dr. Ma JianMr. Chow Ming Sang NOMINATION COMMITTEE Dr. Wen Shuhao(Chairman)Mr. Law Cheuk Kin StephenMs. Chan Wing Ki JOINT COMPANY SECRETARIES Ms. Liu ShimeiMs. Chan Sau Ling 盛德律師事務所839 LEGAL ADVISORS As to Hong Kong lawsSidley Austin39/F, Two International Finance Centre8 Finance StreetCentralHong Kong 羅兵咸永道會計師事務所22 AUDITOR PricewaterhouseCoopersCertified Public Accountants andRegistered Public Interest Entity Auditor22/F, Prince’s BuildingCentralHong Kong 大華繼顯（香港）有限公司396 COMPLIANCE ADVISOR UOB Kay Hian (Hong Kong) Limited6/F, Harcourt House39 Gloucester RoadHong Kong REGISTERED OFFICE PO Box 309Ugland HouseGrand CaymanKY1-1104Cayman Islands PO Box 309Ugland HouseGrand CaymanKY1-1104Cayman Islands HEADQUARTERS AND PRINCIPAL PLACE OFBUSINESS IN THE PRC 2 3/F, Second Phase of the InternationalBiomedical Industrial ParkNo. 2 Hongliu RoadFutian DistrictShenzhenPRC PRINCIPAL PLACE OF BUSINESS IN HONG KONG Room 1917, 19/FLee Garden One33 Hysan AvenueCauseway BayHong Kong 33191917 PRINCIPAL SHARE REGISTRAR AND TRANSFEROFFICE Maples Fund Services (Cayman) LimitedPO Box 1093Boundary HallCricket SquareGrand Cayman KY1-1102Cayman Islands Maples Fund Services (Cayman) LimitedPO Box 1093Boundary HallCricket SquareGrand Cayman KY1-1102Cayman Islands HONG KONG SHARE REGISTRAR Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong 卓佳證券登記有限公司1617 STOCK CODE 2228 The Company's shares are listed on the Main Board ofThe Stock Exchange of Hong Kong Limited Stock code: 2228 www.xtalpi.com COMPANY WEBSITEwww.xtalpi.com A summary of the published results and of the assets and liabilities of theGroup for the last five financial years is set out below: (i)(ii)(iii) We are a quantum physics-based, AI-powered, and robotics-driven,innovative R&D platform. We adopt a combination of quantum physics-based first-principles calculation3, AI, high performance cloud computing,and scalable and standardised robotic automation to provide drug andmaterial science R&D solutions and services to global and domesticcompanies in the pharmaceutical and material science (including agritech,energy and new chemicals, and cosmetics) industries and beyond. 3 We have a diverse customer base, ranging from start-ups to globalbiotechnology and pharmaceutical companies, as well as unicorns andleading companies in the field of new materials. Our customer baseincludes 17 of the top 20 global biotechnology and pharmaceuticalcompanies, which we believe is an indicator of the calibre of our solutionsand services. With operations in both China and the U.S., we strive to takeadvantage of the best capabilities and resources available to us in eachregion to meet the evolving needs of our customers and collaboratorsand academic partners. We have well-established and longstandingrelationships with many of the world’s leading biotechnology andpharmaceutical conglomerates and leading companies in the field of newmaterials, such as Pfizer Inc., Johnson & Johnson, Merck KGaA, Darmstadt,Germany, and Sinopec Shanghai Research Institute many of which are ourrepeat customers. 2017 VISION 4 Our vision is becoming the global leader in quantum physics-based4, AI-powered drug and material science R&D. MISSION 4 Our mission is a world of smarter science, better lives. We aim toaccelerate the design and discovery of novel drugs and materialsleveraging quantum physics4, AI and robotic automation. CORPORATE AND CAPITAL MARKET MILESTONES 2025XtalPiMSCIMSCI100 In 2025, XtalPi was included in the MSCI China Small Cap Index, MSCIChina Index and HKEX Tech 100 Index. This recognises our growthpotential by international capital markets, enhances our global visibilityand underscores our leading position in the technology industry. 3 3Quantum physics is the study of ma